| Previous Close | 35.97 |
| Open | 36.10 |
| Bid | 35.84 x 11300 |
| Ask | 35.85 x 4300 |
| Day's Range | 35.77 - 36.12 |
| 52 Week Range | 29.83 - 36.21 |
| Volume | 7,089,791 |
| Avg. Volume | 17,208,645 |
| Market Cap | 213.15B |
| Beta | 1.06 |
| PE Ratio (TTM) | 26.22 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.61%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Motley Fool•17 minutes ago
This Trial Failure Dropped Versartis Inc 86.6% and Lifted Ascendis Pharma 51.4%
One biopharma's loss is another biopharma's gain when it comes to rare disease drug trials.
- Motley Fool•2 hours ago
AstraZeneca Stock Upgraded: What You Need to Know
Bernstein sees opportunity in a buyout target.
- Zacks•5 hours ago
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.
